Clinical Takeaway
Trauma-focused therapies remain effective for PTSD even when patients are actively using cannabis, including those with co-occurring substance use disorders. Clinicians should not withhold or delay evidence-based PTSD treatment due to a patient’s cannabis use, as it does not appear to undermine therapeutic outcomes.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a significant clinical gap by quantifying whether standard trauma-focused PTSD treatments maintain efficacy in the substantial subset of patients with concurrent cannabis use and comorbid substance use disorders, populations typically excluded from or underrepresented in efficacy trials. Understanding treatment outcomes across cannabis use patterns is essential for clinicians managing PTSD+SUD comorbidity, as cannabis use is highly prevalent in this population yet evidence-based guidance on treatment selection remains limited. These findings inform whether current evidence-based trauma protocols require modification or alternative approaches for cannabis-using patients with co-occurring PTSD and SUDs.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis addresses a clinically relevant gap by examining whether trauma-focused treatments remain effective for patients with comorbid PTSD, cannabis use, and other substance use disorders, a population often excluded from traditional efficacy trials. The individual patient data approach strengthens the analysis beyond aggregate findings, yet several important caveats warrant consideration: the subset of four RCTs limits generalizability, cannabis use was not necessarily the primary focus of the original trials, and the data do not distinguish between cannabis as self-medication versus as a confounding variable affecting treatment engagement or outcomes. Additionally, the heterogeneity of trauma-focused interventions and the spectrum of cannabis use patterns across participants may obscure treatment effects specific to cannabis users. Rather than avoiding evidence-based trauma treatment in patients who use cannabis, clinicians should proceed with these interventions while actively monitoring for cannabis use patterns, addressing substance use collaboratively within the therapeutic relationship, and individualizing approaches based on whether cannabis appears to impair treatment participation or recovery.